Xilio Therapeutics, Inc.’s Post

Register today! Study Overview webinars are being offered to review our #breastcancer clinical trial, NRG-BR008 - the HERO Study (Her2 Radiation Optimization). Refer to the memo posted on the CTSU for details on how to register. #bcsm #BreastCancerAwarenessMonth

🔬 Attention Healthcare Providers! Phase 2 Registration for DEX Z-Codes® Now Open Starting August 1, 2024, you can begin registering tests that fall within the scope of phase 2 of the DEX Z-Codes® for certain molecular diagnostic test services. As part of our recently updated Molecular Pathology Reimbursement Policy (Professional and Facility), which took effect on June 1, 2024, They are implementing this important requirement. 🔍 What’s New? Phase 2 Scope: Tests subject to phase 2open_in_new must include the appropriate Z-code on their claims. Effective Date: Claims with dates of service on or after November 1, 2024, will be considered for reimbursement if they comply with the Z-code requirement. Test Code Registration Phases: UHC send you timely reminders about each registration phase. You’ll receive notifications at least 30 days in advance of the start date. Phase 2 Registration: Get ahead by registering your tests starting August 01, 2024. 🔗 #HealthcareBilling #MolecularDiagnostics #ZCodes #Reimbursement Sonora Quest Laboratories/ Laboratory Sciences of Arizona Quest Diagnostics UHC Labcorp Palmetto GBA

This week, we reaffirmed our 2024 strategic priorities, and we have an exciting 2H ahead! Our top priority remains preparing for commercialization, and we look forward to bringing the investigational ARC-EX® System to the Spinal Cord Injury (SCI) Community in the US later this year. *   Here’s more detail:  ➡️ ARC-EX® commercial launch. We intend to launch our ARC-EX Therapy for people with SCI in the US in Q4 2024, pending Food and Drug Administration (FDA) clearance.   ➡️ ARC-IM ® interim data publication. We expect a peer-reviewed publication in a top-tier medical journal detailing the results of the first 10+ patients implanted with investigational ARC-IM Therapy to address blood pressure instability after SCI. ➡️ ARC-IM pivotal study commencement. We are preparing to launch our global pivotal study, called Empower BP, for investigational ARC-IM Therapy to address blood pressure instability after SCI, pending FDA Investigational Device Exemption approval.  ➡️ ARC-BCI™ Therapy advancement. Clinical and development activities for our investigational ARC-BCI System continue and several additional ARC-BCI System implants are expected in 2H 2024 and 1H 2025 as part of the ongoing clinical feasibility study with partners at .NeuroRestore and @CEA-Clinatec.  Here are our unaudited Q2 2024 financial highlights: ✅ We plan to publish our Half Year 2024 financial statements on September 10, 2024.  ✅ The net cash balance on June 30, 2024, was EUR 32.1 million.   To learn more about ONWARD Medical’s commitment to partnering with the SCI Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit www.ONWD.com    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.  #EmpoweringMovement #SCI #StrategicPriorities d4871b2d-3d8c-4e4b-99fd-2774a1714fb6 (onwd.com)   

🔬Dr. David Systrom Discusses OMF’s LIFT Clinical Trial 🔬 Today Dr. David Systrom sits down to chat about OMF's first clinical trial, The Life Improvement Trial (LIFT). Watch the video interview 👉 https://ow.ly/PH9750Q5gSn. What is The LIFT? Conducted under the direction of David Systrom, MD, Director of our Harvard Collaboration and Jonas Bergquist, MD, PhD, OMF’s Chief Medical Officer and Director of the Uppsala University Collaboration, The LIFT is a randomized, double-blind placebo trial that will investigate two particular drugs: Pyridostigmine (commonly known as Mestinon) and low-dose naltrexone (LDN) separately and together as a combination. Dr. Systrom speaks more on trial setup, expected timelines of the trial, why this is an important first step, and more.

View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z

Modular ATP & APPRAISE ATP data continues to show the importance of evidence-based medicine and BSC’s commitment to this space. We are excited about these results to help further advance CRM therapy. #BSCCardiology #HRS2024

The program for #earlydetection of #colorectalcancer (#CRC) run in #Catalonia, makes me feel #proudof how the public resources are used for well thought #publichealth initiatives. Everybody between 50 and 69 years old receives a letter every two years inviting them to participate, free of charge, in the program. All what you have to do is to take the letter to a #pharmacy, where you will be given a sample collection device. The device is barcoded with a unique ID which the pharmacy will match with your public #healthcare ID number. Then you collect at home the sample for a #fecaloccultblood test (#FOB) and you bring the sample back to the pharmacy. The pharmacies get the devices collected daily and the sample is analyzed in a #clinicallaboratory. The results are mailed back in days if normal, and if abnormal the individual is contacted by phone to immediately arrange an appointment for deeper clinical follow up. Catalan Institute of Oncology Sistema de Salut de Catalunya #laboratorymedicine #biomarkers #IVD

Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this webinar Sara Riordan MS, CGC, Genome Medical;  Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register: https://lnkd.in/gRg3gwC4

View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z

View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z